| SFDA Approved Use |
Treatment of prostate cancer in the following settings:
• In the treatment of metastatic prostate cancer where Goserelin acetate has demonstrated comparable survival benefits to surgical castrations • In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Goserelin acetate has demonstrated comparable survival benefits to an anti-androgen • As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival and overall survival • As neo-adjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Goserelin acetate has demonstrated improved disease-free survival Goserelin acetate 10.8 mg is indicated in the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women. |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.